Immune Activation Is Associated With Neurocognitive Performance in Ugandan Adolescents Living With HIV
- 1 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 97 (3) , 296-304
Abstract
We examined relationships between neurocognition and immune activation in Ugandan adolescents with perinatally acquired HIV (PHIV). Eighty-nine adolescents in Kampala, Uganda (32 virally suppressed [+ and CD8+) activation and gut markers. Spearman rank correlations and median regressions examined associations between test performance and immune activation. The median [IQR] age was 15 [13–16] years, and 40% were girls. The median time on antiretroviral therapy was 10 years [7–11] for PHIV; 87% had viral load P = 0.05) and significantly worse on tests of executive functioning and delayed recall (P's ≤ 0.05). Overall, monocyte activation significantly correlated with worse test performance on global z-score (r = 0.21, P = 0.04), attention, processing speed, and motor speed (r = 0.2–0.3, P ≤ 0.01). T-cell activation was significantly correlated with worse performance on tests of learning, executive functioning, and working memory (r = 0.2–0.4, P ≤ 0.04). In PHIV, after adjusting for age, sex, and antiretroviral therapy duration, activated CD4 T cells remained associated with worse memory (β-0.3, 95% CI: −0.55 to −0.07, P = 0.01). PHIV with virologic suppression on antiretroviral therapy shows evidence of worse neurocognitive test performance compared with controls. Monocyte and T-cell activation is correlated with worse neurocognition in Ugandan youth with and without HIV, which has not been previously investigated in this setting.Keywords
Funding Information
- National Institute of Child Health and Human Development (K23HD088295)
- Division of Intramural Research (U01AI168630)
This publication has 52 references indexed in Scilit:
- Developments in Neuroprotection for HIV-Associated Neurocognitive Disorders (HAND)Current HIV/AIDS Reports, 2022
- Cognitive outcomes at ages seven and nine years in South African children from the children with HIV early antiretroviral (CHER) trial: a longitudinal investigationJournal of the International AIDS Society, 2021
- Construct Validity Supports Use of a Novel, Tablet-Based Neurocognitive Assessment for Adolescents and Young Adults Affected by Perinatal HIV from Vulnerable Communities in the United StatesAIDS and Behavior, 2020
- State of the Mind: Growing up with HIVPediatric Drugs, 2020
- Blood-based inflammation biomarkers of neurocognitive impairment in people living with HIVJournal of NeuroVirology, 2020
- Sex Differences in Neurocognitive Function in Adults with HIV: Patterns, Predictors, and MechanismsCurrent Psychiatry Reports, 2019
- Role of T Lymphocytes in HIV NeuropathogenesisCurrent HIV/AIDS Reports, 2019
- Neurocognitive decline in HIV patients is associated with ongoing T‐cell activation in the cerebrospinal fluidAnnals of Clinical and Translational Neurology, 2015
- Neurologic disease in HIV‐infected children and the impact of combination antiretroviral therapyReviews in Medical Virology, 2014
- HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictorsJournal of NeuroVirology, 2010